Thermo Fisher (TMO) | Financial Analysis & Statements
Thermo Fisher Scientific Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
12.2B
Gross Profit
5.0B
41.02%
Operating Income
2.3B
18.85%
Net Income
2.0B
16.13%
EPS (Diluted)
$5.21
Balance Sheet Metrics
Total Assets
110.3B
Total Liabilities
56.8B
Shareholders Equity
53.5B
Debt to Equity
1.06
Cash Flow Metrics
Operating Cash Flow
3.0B
Free Cash Flow
3.0B
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Thermo Fisher Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44.6B | 42.9B | 42.9B | 44.9B | 39.2B |
| Cost of Goods Sold | 26.3B | 25.2B | 25.8B | 25.9B | 19.6B |
| Gross Profit | 18.2B | 17.7B | 17.1B | 19.0B | 19.6B |
| Gross Margin % | 40.9% | 41.3% | 39.9% | 42.2% | 50.1% |
| Operating Expenses | |||||
| Research & Development | 1.4B | 1.4B | 1.3B | 1.5B | 1.4B |
| Selling, General & Administrative | 8.7B | 8.6B | 8.4B | 9.0B | 8.0B |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 10.1B | 10.0B | 9.8B | 10.5B | 9.4B |
| Operating Income | 8.1B | 7.7B | 7.3B | 8.5B | 10.2B |
| Operating Margin % | 18.2% | 18.0% | 17.1% | 18.9% | 26.1% |
| Non-Operating Items | |||||
| Interest Income | 993.0M | 1.1B | 879.0M | 272.0M | 43.0M |
| Interest Expense | 1.4B | 1.4B | 1.4B | 726.0M | 536.0M |
| Other Non-Operating Income | -374.0M | -367.0M | -524.0M | -218.0M | -891.0M |
| Pre-tax Income | 7.3B | 7.0B | 6.3B | 7.8B | 8.8B |
| Income Tax | 547.0M | 657.0M | 284.0M | 703.0M | 1.1B |
| Effective Tax Rate % | 7.5% | 9.3% | 4.5% | 9.0% | 12.5% |
| Net Income | 6.7B | 6.3B | 6.0B | 7.0B | 7.7B |
| Net Margin % | 15.1% | 14.8% | 13.9% | 15.5% | 19.7% |
| Key Metrics | |||||
| EBITDA | 11.9B | 11.9B | 11.5B | 12.1B | 12.2B |
| EPS (Basic) | $17.77 | $16.58 | $15.52 | $17.75 | $19.62 |
| EPS (Diluted) | $17.74 | $16.53 | $15.45 | $17.63 | $19.46 |
| Basic Shares Outstanding | 377000000 | 382000000 | 386000000 | 392000000 | 394000000 |
| Diluted Shares Outstanding | 377000000 | 382000000 | 386000000 | 392000000 | 394000000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Thermo Fisher Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 9.9B | 4.0B | 8.1B | 8.5B | 4.5B |
| Short-term Investments | 253.0M | 1.6B | - | - | - |
| Accounts Receivable | 8.9B | 8.2B | 8.2B | 8.1B | 8.0B |
| Inventory | 5.4B | 5.0B | 5.1B | 5.6B | 5.1B |
| Other Current Assets | 2.6B | 2.0B | 1.8B | 1.6B | 1.6B |
| Total Current Assets | 28.7B | 22.1B | 24.6B | 25.2B | 20.1B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 114.6B | 107.2B | 104.7B | 99.8B | 104.0B |
| Intangible Assets | 15.8B | 15.5B | 16.7B | 17.4B | 20.1B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 5.9B | 4.5B | 4.0B | 4.0B | 4.6B |
| Total Non-Current Assets | 81.6B | 75.2B | 74.1B | 71.9B | 75.0B |
| Total Assets | 110.3B | 97.3B | 98.7B | 97.2B | 95.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.6B | 3.1B | 2.9B | 3.4B | 2.9B |
| Short-term Debt | 3.5B | 2.2B | 3.6B | 5.6B | 2.5B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 15.2B | 13.3B | 14.0B | 17.0B | 13.4B |
| Non-Current Liabilities | |||||
| Long-term Debt | 35.9B | 29.1B | 31.3B | 28.9B | 32.3B |
| Deferred Tax Liabilities | 1.5B | 1.3B | 1.9B | 2.8B | 3.8B |
| Other Non-Current Liabilities | 4.3B | 4.0B | 4.6B | 4.2B | 4.5B |
| Total Non-Current Liabilities | 41.6B | 34.3B | 37.9B | 36.0B | 40.7B |
| Total Liabilities | 56.8B | 47.6B | 51.9B | 53.0B | 54.1B |
| Equity | |||||
| Common Stock | 445.0M | 444.0M | 442.0M | 441.0M | 439.0M |
| Retained Earnings | 59.2B | 53.1B | 47.4B | 41.9B | 35.4B |
| Treasury Stock | 22.3B | 19.2B | 15.1B | 12.0B | 8.9B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 53.5B | 49.7B | 46.8B | 44.1B | 41.0B |
| Key Metrics | |||||
| Total Debt | 39.4B | 31.3B | 34.9B | 34.5B | 34.9B |
| Working Capital | 13.5B | 8.8B | 10.6B | 8.2B | 6.7B |
Balance Sheet Composition
Thermo Fisher Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 6.7B | 6.3B | 6.0B | 7.0B | 7.7B |
| Depreciation & Amortization | 2.8B | 3.1B | 3.4B | 3.4B | 2.6B |
| Stock-Based Compensation | 310.0M | 301.0M | 278.0M | 307.0M | 230.0M |
| Working Capital Changes | -1.8B | -334.0M | -495.0M | -1.0B | -1.5B |
| Operating Cash Flow | 7.8B | 8.7B | 8.4B | 9.1B | 8.5B |
| Investing Activities | |||||
| Capital Expenditures | -1.5B | -1.3B | -1.4B | -2.2B | -2.5B |
| Acquisitions | -4.0B | -3.1B | -3.7B | -39.0M | -19.4B |
| Investment Purchases | -383.0M | -3.4B | - | - | - |
| Investment Sales | 1.8B | 2.0B | 70.0M | 15.0M | 8.0M |
| Investing Cash Flow | -4.0B | -5.8B | -5.1B | -2.2B | -21.9B |
| Financing Activities | |||||
| Share Repurchases | -3.0B | -4.0B | -3.0B | -3.0B | -2.0B |
| Dividends Paid | -636.0M | -583.0M | -523.0M | -455.0M | -395.0M |
| Debt Issuance | 7.8B | 1.2B | 5.9B | 3.2B | 18.1B |
| Debt Repayment | -3.5B | -3.6B | -7.7B | -4.1B | -11.7B |
| Financing Cash Flow | 706.0M | -6.8B | -5.6B | -6.5B | 6.6B |
| Free Cash Flow | 6.3B | 7.3B | 6.9B | 6.9B | 6.8B |
| Net Change in Cash | 4.5B | -4.0B | -2.3B | 469.0M | -6.8B |
Cash Flow Trend
Thermo Fisher Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.84
Forward P/E
17.16
Price to Book
3.31
Price to Sales
3.86
PEG Ratio
2.29
Profitability Ratios
Profit Margin
15.15%
Operating Margin
17.89%
Return on Equity
13.52%
Return on Assets
5.00%
Financial Health
Current Ratio
1.53
Debt to Equity
82.91
Beta
0.97
Per Share Data
EPS (TTM)
$18.18
Book Value per Share
$141.96
Revenue per Share
$120.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TMO | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Idexx Laboratories | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
| Natera | 27.4B | - | 15.75 | -14.32% | -9.03% | 12.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






